menu
    • menu

    Company profile for CNS Pharmaceuticals

    NEW Drugs in Dev: 4
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CNS is developing Berubicin, a breakthrough drug for the treatment of the most deadly form of brain cancer. Berubicin was created at MD Anderson Cancer Center, the largest cancer and research institute in the world. Berubicin’s Phase I clinical trial yielded promising results showing clinical activity in 44% of patients*. Berubicin is the first of its class of drugs to cross the blood brain barrier (BBB) and reach cancer cel...
    CNS is developing Berubicin, a breakthrough drug for the treatment of the most deadly form of brain cancer. Berubicin was created at MD Anderson Cancer Center, the largest cancer and research institute in the world. Berubicin’s Phase I clinical trial yielded promising results showing clinical activity in 44% of patients*. Berubicin is the first of its class of drugs to cross the blood brain barrier (BBB) and reach cancer cells in brain tumor patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CNS PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2100 West Loop South Freeway , Houston, TX
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://republic.queue-it.net/softblock/?c=republic&e=13&t=https%3A%2F%2Frepublic.com%2Fcns-pharmaceuticals&cid=en-US
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/cns_pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CNS Pharmaceuticals CFO Highlights Recent $22.5M Financing
    CNS Pharmaceuticals CFO Highlights Recent $22.5M Financing

    08 Jun 2026

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cns-pharmaceuticals-cfo-steve-oloughlin-highlights-companys-recent-22-1173817

    ACCESSWIRE
    08 Jun 2026
    Share Share
    CNS Pharmaceuticals CEO Highlights Strategic Transformation
    CNS Pharmaceuticals CEO Highlights Strategic Transformation

    20 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-20/cns-pharmaceuticals-ceo-rami-levin-participates-in-virtual-investor-ceo-connect-segment-highlighti

    PHARMIWEB
    20 May 2026
    Share Share
    CNS Pharmaceuticals Reports Q1 2026 Financial Results
    CNS Pharmaceuticals Reports Q1 2026 Financial Results

    14 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-14/cns-pharmaceuticals-reports-first-quarter-2026-financial-results-and-highlights-strategic-transforma

    PHARMIWEB
    14 May 2026
    Share Share
    CNS Pharma Closes Oversubscribed $22.5M Private Placement
    CNS Pharma Closes Oversubscribed $22.5M Private Placement

    04 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-04/cns-pharmaceuticals-announces-oversubscribed-225-million-private-placement-financing

    PHARMIWEB
    04 May 2026
    Share Share
    CNS Pharma Unveils Strategy For High-Value Neurology & Oncology
    CNS Pharma Unveils Strategy For High-Value Neurology & Oncology

    11 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-11/cns-pharmaceuticals-launches-new-corporate-strategy-focused-on-building-a-high-value-neurology-and-o

    PHARMIWEB
    11 Mar 2026
    Share Share
    CNS Pharma Names Lynne Kelley, MD, FACS, Chief Medical Officer
    CNS Pharma Names Lynne Kelley, MD, FACS, Chief Medical Officer

    02 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-02/cns-pharmaceuticals-appoints-lynne-kelley-md-facs-as-chief-medical-officer-completing-executive

    PHARMIWEB
    02 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search